Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer

NCT01961544 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Breast Cancer

Interventions

DRUG: Eribulin mesylate

Sponsor

Eisai Korea Inc.